Metformin monotherapy in melanoma: A pilot, open-label, prospective and multicentric study indicates no benefit.
Fiche publication
Date publication
janvier 2017
Journal
Pigment cell & melanoma research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
Tous les auteurs :
Montaudié H, Cerezo M, Bahadoran P, Roger C, Passeron T, Machet L, Arnault JP, Verneuil L, Maubec E, Aubin F, Granel F, Giacchero D, Hofman V, Lacour JP, Maryline A, Balotti R, Rocchi S
Lien Pubmed
Résumé
Targeted therapies and immunotherapies have significantly improved the prognosis of patients with advanced melanoma (Long et al., 2015; Robert et al., 2015a; Robert et al., 2015b; Ascierto et al., 2015). Unfortunately, treatment failure due to primary and secondary drug resistance are still observed and therefore there is an urgent need to identify new anti-melanoma agents. The oral anti-diabetic drug metformin belongs to the family of biguanides and it is the most widely used antidiabetic drug in the world. This article is protected by copyright. All rights reserved.
Référence
Pigment Cell Melanoma Res. 2017 Jan;: